Company Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 15:59:58 17/05/2024 BST 5-day change 1st Jan Change
2,041 DKK +0.74% Intraday chart for Genmab A/S +1.90% -5.29%

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees: 2,286

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 63 31/12/98
Director of Finance/CFO 46 31/12/06
Chief Operating Officer 53 22/03/20
Chief Tech/Sci/R&D Officer 51 31/12/16
Public Communications Contact - 10/03/19
Human Resources Officer 46 -
Corporate Officer/Principal 67 08/02/17
Corporate Officer/Principal 71 31/12/00
General Counsel 63 31/12/01

Members of the board

Members of the board TitleAgeSince
Chairman 63 31/12/16
Director/Board Member 73 31/10/03
Director/Board Member 64 31/12/15
Director/Board Member 59 28/03/22
Director/Board Member 57 31/12/14
Director/Board Member 73 31/12/14
Director/Board Member 51 28/03/19
Director/Board Member 49 31/12/21
Director/Board Member 50 31/12/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,129,923 65,134,985 ( 98.50 %) 981,465 ( 1.484 %) 98.50 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.896 %
3,237,113 4.896 % 908 M kr
Global Opportunities (GO) Capital Asset Management BV
3.556 %
2,351,225 3.556 % 659 M kr
GENMAB A/S
2.327 %
1,538,803 2.327 % 432 M kr
ATP Fondsmaeglerselskab A/S
2.318 %
1,532,909 2.318 % 430 M kr
600,497 0.9082 % 168 M kr
Industriens Pensionsforsikring A/S
0.7794 %
515,356 0.7794 % 145 M kr
Nykredit Bank A/S (Investment Management)
0.4854 %
320,984 0.4854 % 90 M kr
Amundi Asset Management SA (Investment Management)
0.3114 %
205,882 0.3114 % 58 M kr
State Street Global Advisors Ltd.
0.2517 %
166,422 0.2517 % 47 M kr
Danske Bank A/S (Investment Management)
0.2157 %
142,640 0.2157 % 40 M kr
NameEquities%Valuation
AllianceBernstein LP
2.307 %
15,254,347 2.307 % 419 M kr
BlackRock Advisors LLC
0.7591 %
5,019,269 0.7591 % 138 M kr
Capital Research & Management Co. (International Investors)
0.6614 %
4,373,277 0.6614 % 120 M kr
Harding Loevner LP
0.4983 %
3,294,728 0.4983 % 90 M kr
Wellington Management Co. LLP
0.3526 %
2,331,814 0.3526 % 64 M kr
RBC CMA LLC
0.2732 %
1,806,502 0.2732 % 50 M kr
Renaissance Technologies LLC
0.2055 %
1,358,600 0.2055 % 37 M kr
Wells Fargo Bank NA
0.1931 %
1,276,518 0.1931 % 35 M kr
First Trust Advisors LP
0.1860 %
1,229,570 0.1860 % 34 M kr
U.S. Trust Company of Delaware
0.1677 %
1,109,117 0.1677 % 30 M kr

Holdings

NameEquities%Valuation
1,538,803 2.33% 431,615,345 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab A/S(GMAB)